moomoo ID:NaN
Log Out
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01530 3SBIO > Financial Statement > Income statement
01530 3SBIO
Do not show
Hide blank lines
-0.51% 3.09B 14.22% 6.38B 15.29% 3.11B 5.07% 5.59B
Operating income
-0.51% 3.09B 14.22% 6.38B 15.29% 3.11B 5.07% 5.59B
Cost of sales
-1.23% -526.38M -4.08% -1.11B -8.76% -519.99M -14.87% -1.06B
Operating expenses
-1.23% -526.38M -4.08% -1.11B -8.76% -519.99M -14.87% -1.06B
Gross profit
-0.86% 2.56B 16.60% 5.28B 16.69% 2.59B 3.00% 4.52B
Selling expenses
0.18% -1.15B -15.07% -2.32B -18.49% -1.15B -3.54% -2.02B
Administrative expenses
-16.53% -195.06M 17.95% -371.49M -12.50% -167.38M 33.02% -452.78M
Research and development expenses
14.71% -294.11M -27.70% -753.87M -35.58% -344.85M -12.11% -590.34M
Operating interest expense
-7.21% -34.66M 17.94% -66.53M 25.88% -32.33M 25.95% -81.07M
Special items of operating profit
48.91% 225.81M 139.33% 146.05M 294.12% 151.65M -456.74% -371.3M
Operating profit
7.18% 1.12B 88.79% 1.91B 24.59% 1.04B -18.19% 1.01B
Share of profits of associates
22.71% -11.65M -13.58% -33.92M 16.72% -15.07M -86.66% -29.87M
Share of profit from joint venture company
48.83% -654K -505.33% -3.18M -1,026.09% -1.28M -110.56% -525K
Earning before tax
7.69% 1.1B 90.86% 1.87B 25.32% 1.03B -19.94% 979.13M
-21.67% -164.04M -15.95% -241.19M -1.50% -134.83M 14.32% -208.02M
After-tax profit from continuing operations
5.57% 940.66M 111.07% 1.63B 29.93% 891.03M -21.33% 771.11M
Earning after tax
5.57% 940.66M 111.07% 1.63B 29.93% 891.03M -21.33% 771.11M
Minority profit
-75.81% -13.86M 63.40% -23.67M 52.90% -7.88M -1,093.47% -64.69M
Profit attributable to shareholders
6.19% 954.52M 97.57% 1.65B 27.96% 898.91M -14.16% 835.79M
Basic earnings per share
11.43% 0.39 96.97% 0.65 25.00% 0.35 -13.16% 0.33
Diluted earnings per share
8.82% 0.37 87.88% 0.62 25.93% 0.34 -13.16% 0.33
Currency Unit
Accounting Standards
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
--Ernst & Young accounting firm--Ernst & Young accounting firm

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Sansheng Pharmaceutical (the "Company" or "Sansheng Pharmaceutical", together with its subsidiaries collectively referred to as the "Group") is a leading biotechnology company in the people's Republic of China (the "PRC"). As a pioneer in the biotechnology industry in China, the Group has rich experience in R & D, production and marketing of biomedical products. The Group's core products include Tabio, Recombinant Human Erythropoietin ("rhEPO") products iBio and Cyber, and Yisaipu Mendi. Tabio is the only commercial recombinant human thrombopoietin ("rhTPO") product in the world. In the first half of 2022, Terbiao had 66.0% of the market for thrombocytopenia treatment in mainland China by sales, according to IQVIA1. With two rhEPO products, the Group has been the market leader in rhEPO in mainland China for two decades, with a total share of 44.1% in the first half of 2022. Yisepu is a tumor necrosis factor ("TNF") α inhibitor product, occupying 28.2% of the TNF α market in mainland China in the first half of 2022. In the first half of 2022, Mandy had a dominant 71.9% market share in mainland China's minoxidil tincture market by sales, according to the China Pharmaceutical Association. The Group also increases its products through internal research and development ("R & D") and a number of external strategies to expand the field of treatment. At the same time, the Group has increased its revenue scale through strategic bureau contract development and production operations ("CDMO") business, which has been in operation since December 2021 and its business scale in mainland China has increased rapidly. On June 30, 2022, of the 33 products under research and development by the Group, 26 were developed as innovative drugs in mainland China. Among the 33 products under study, 18 were antibodies, 7 were other biological products and 8 were small molecular drugs. The Group has 11 oncology products in progress; 13 products in progress targeting autoimmune diseases (including rheumatoid arthritis ("RA")), and other diseases, including obstinate gout and eye diseases (such as age-related macular degeneration ("AMD"); 9 nephrology products in progress; and 1 dermatology product in progress. The industry in which the Group operates is very attractive. Biotechnology has brought about great changes in the pharmaceutical industry by meeting unmet medical needs and providing innovative treatments for a wide range of human diseases. In mainland China, the biopharmaceutical industry is strongly supported by the government and recognized by the State Council as an important strategic emerging industry. Strong government support and the growing adoption of biopharmaceutical products by doctors in mainland China have contributed to the strong growth of the industry. The Group is expanding around the world. Outside the mainland of China, Terbio has been approved by nine countries; iBio has been approved by 23 countries; and Yisep has been approved by 15 countries. In the long run, the Group's goal is to market its products in developed countries. The Group also cooperates with international partners to develop and market the Group's products under development, such as pegsiticase and monoclonal antibodies against programmed death receptor 1 ("PD-1"). The Group aims to focus on research and development to provide innovative treatments for patients in mainland China and around the world. As at 30 June 2022, the Group had operating facilities in Shenyang, Shanghai, Hangzhou and Shenzhen (all located in mainland China) and Cuomo in Italy with a staff of 5160. The Group's pharmaceutical products are promoted and sold in all provinces, autonomous regions and municipalities directly under the Central Government in mainland China and in a number of overseas countries and regions. During the six months ended 30 June 2022 (the "reporting period"), the Group's national distribution network sold the Group's products to more than 7500 hospitals and medical institutions in mainland China.
CEO: Jing Lou
Market: Hong Kong motherboard
Listing Date: 06/11/2015
Hot List
SymbolLatest price%Chg